(+/-)-trans-4-phenyl-3-hydroxymethyl-1-methylpiperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (+/-)-trans-4-phenyl-3-hydroxymethyl-1-methylpiperidine
• 英文别名: trans-(1-methyl-4-phenyl-piperidin-3-yl)-methanol；1-Methyl-4-phenyl-3-piperidinemethanol；(1-methyl-4-phenylpiperidin-3-yl)methanol
• 化学式: C₁₃H₁₉NO
• 分子量: 205.3
• InChiKey: PTRITADCAOWGKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (+/-)-trans-4-phenyl-3-hydroxymethyl-1-methylpiperidine 生成 非莫西汀
  参考文献：
  名称：

  4-Phenylpiperidine compounds

  摘要：

  本发明涉及新型3-取代的1-烷基-4-苯基哌啶，可用作抗抑郁和抗帕金森药物，并涉及其生产。

  公开号：

  US04007196A1
• 作为产物：
  描述：

  (+)-Methyl 4β-(4-Bromophenyl)-1-methylpiperidine-3β-carboxylate 在 LiAlH4 作用下， 以 四氢呋喃 为溶剂， 生成 (+/-)-trans-4-phenyl-3-hydroxymethyl-1-methylpiperidine
  参考文献：
  名称：

  Monomeric and dimeric heterocycles, and therapeutic uses thereof

  摘要：

  该发明提供了以下式（I）的化合物：X—L—X1（I），其中X和X1为取代的哌啶、环己烷或四氢吡喃环，L为连接X和X1之间的连接基团；以及包括式I化合物的药物组合物；用于制备式I化合物的中间体和方法；以及治疗药物成瘾、帕金森病、抑郁症或需要使用可卡因的疾病的治疗方法，包括向需要此类治疗的哺乳动物施用式I化合物或其药用盐。

  公开号：

  US06440996B1

文献信息

• Heterocyclic glycerol derivatives and their use as anti-hypertensive
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US04962096A1

  公开（公告）日：1990-10-09

  A novel glycerol derivative which is effective to reduce blood pressure has the formula: ##STR1## wherein R.sup.1 is an alkyl group having 10-22 carbon atoms, R.sup.2 is lower acyl, benzoyl, aryl, mono-, di- or triarylalkyl, alkyl, cycloalkyl, or cycloalkylalkyl; Q is substituted or unsubstituted alkylene containing 1-4 carbon atoms, l is 0 or 1; Y is a nitrogen-containing heterocyclic group or a nitrogen-containing bridged heterocyclic group (--(Q).sub.l -- is attached to a carbon atom contained in a hetero-ring of the heterocyclic group) in which Y is the bridged heterocyclic group where l is 0; and each of R.sup.5, R.sup.6 and R.sup.7 is hydrogen, lower alkyl, aryl or aralkyl.

  一种新型的甘油衍生物，有效降低血压，其化学式为：##STR1## 其中R.sup.1是具有10-22个碳原子的烷基基团，R.sup.2是较低的酰基、苯甲酰基、芳基、单、二或三芳基烷基、烷基、环烷基或环烷基烷基；Q是取代或未取代的含有1-4个碳原子的烷基，l为0或1；Y是含氮杂环基团或含氮桥接的杂环基团（--(Q).sub.l --连接到杂环基团的杂环环中的碳原子）其中Y是杂环基团，l为0；R.sup.5、R.sup.6和R.sup.7中的每一个是氢、较低的烷基、芳基或芳基烷基。
• [EN] NOVEL PROCESS FOR THE PREPARATION OF 4-ARYL-3-HYDROXYMETHYL-1-METHYLPIPERIDINES.<br/>[FR] NOUVEAU PROCEDE DE PREPARATION DE 4-ARYL-3-HYDROXYMETHYL-1-METHYLPIPERIDINES
  申请人：NATCO PHARMA LTD

  公开号：WO2004043921A1

  公开（公告）日：2004-05-27

  A novel, improved, and general process for the preparation of 4-aryl-3-hydroxymethyl-1-methylpiperidines is disclosed in the present invention. 4-(4-Fluorophenyl)-3-hydroxymethyl-1-methylpiperidine is a well-known intermediate in making the anti-depressant drug, paroxetine ((-)-trans-4-p-fluorophenyl-3-(3',4'-methylenedioxy-phenoxymethyl)piperidine). Novel N-methyl-N-[3-(4-substitutedphenyl (F, Me, OMe))-3-hydroxy]propylamines are prepared from the Mannich salts such as 3-dimethylamino- or 3-(N-methyl-N-benzylamino)-4'-substituted (F, Me, OMe) propiophenone hydrochlorides by conventional methods. The N-methyl-N-[3-(4-substitutedphenyl (H, F, Me, OMe))-3-hydroxy]propylamines thus obtained are reacted with ethyl or methyl acrylate to get the corresponding Michael addition products. The hydroxy group present in the Michael addition products is converted into a facile leaving group and treated with a strong base to get 4-aryl-N-methylpiperidine-3-carboxylates via the intramolecular cyclization in good yields. Reduction of the ester group present in these piperidine-3-carboxylates gave the title compounds as crystalline solids. Present process is easily adaptable for commercial preparation of the paroxetine intermediate (4-(4-fluorophenyl)-3-hydroxymethyl-1-methylpiperidine).

  本发明揭示了一种新颖的、改进的、通用的制备4-芳基-3-羟甲基-1-甲基哌啶的方法。4-(4-氟苯基)-3-羟甲基-1-甲基哌啶是制造抗抑郁药物帕罗西汀((-)-trans-4-p-氟苯基-3-(3',4'-亚甲二氧基苯氧甲基)哌啶)的已知中间体。新型的N-甲基-N-[3-(4-取代苯基(F，Me，OMe))-3-羟基]丙胺可通过常规方法从Mannich盐制备而来，例如3-二甲氨基或3-(N-甲基-N-苄基氨基)-4'-取代(F，Me，OMe)丙酮盐酸盐。因此获得的N-甲基-N-[3-(4-取代苯基(H，F，Me，OMe))-3-羟基]丙胺与乙基或甲基丙烯酸酯反应，得到相应的Michael加成产物。Michael加成产物中存在的羟基转化为容易离去的基团，并用强碱处理，通过分子内环化以良好的产率得到4-芳基-N-甲基哌啶-3-羧酸酯。这些哌啶-3-羧酸酯中存在的酯基还原后，得到了晶体固体的目标化合物。目前的方法易于用于商业制备帕罗西汀中间体(4-(4-氟苯基)-3-羟甲基-1-甲基哌啶)。
• PIPERIDINE DERIVATIVES
  申请人：Bruendl M. Michelle

  公开号：US20070142389A1

  公开（公告）日：2007-06-21

  The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein R 6 and R 10 have any of the values defined therefor in the specification; pharmaceutical compositions; methods of treating conditions, diseases, and disorders; and therapeutic combinations.

  本发明提供了化合物I的公式：以及其药用盐，其中R6和R10具有规范中定义的任何值；药物组合；治疗条件、疾病和障碍的方法；以及治疗组合物。
• [EN] AN IMPROVED PROCESS FOR MINIMISING THE FORMATION OF DEHALOGENATED BYPRODUCTS<br/>[FR] PROCÉDÉ AMÉLIORÉ PERMETTANT DE RÉDUIRE AU MINIMUM LA FORMATION DE SOUS-PRODUITS DÉSHALOGÉNÉS
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2015071831A1

  公开（公告）日：2015-05-21

  The present invention provides an improved process for preparation of organic compounds represented by Formula-Z; wherein effectively minimising the formation of dehalogenated by-products is achieved. In the process, the reduction is carried out using suitable reducing agent; more preferably Lithium Aluminium Hydride (LAH) in a solvent system, wherein at least one of the solvent is selected from halogenated solvents, which acts as co-solvent. The process of the present invention is useful for minimising of the formation of dehalogenated by-products during synthesis of various active pharmaceutical ingredients such as Paroxetine Hydrochloride, Cinacalcet, Eletriptan and Asenapine.

  本发明提供了一种改进的有机化合物制备方法，该化合物由Formula-Z表示；在该过程中，有效地最小化了去卤代副产物的形成。在该过程中，使用适当的还原剂进行还原；更好地使用锂铝氢化物（LAH）在溶剂系统中进行还原，其中至少一种溶剂是选自卤代溶剂的协溶剂。本发明的方法对于在合成各种活性药物成分（如盐酸帕罗西汀、西那卡塞特、厄利替普坦和阿塞那平）期间最小化去卤代副产物的形成非常有用。
• Novel process
  申请人：——

  公开号：US20030187269A1

  公开（公告）日：2003-10-02

  A process for the preparation of a compound of formula (1): 1 in which R 1 is an alkyl, arylalkyl, allyl, alkyloxycarbonyl, arylalkyloxycarbonyl, acyl or alkynyl group; and R 2 is substituted phenyl, especially 3,4-methylenedioxyphenyl; and X is hydrogen or a readily removable group, such as chlorine, bromine or iodine.

  一种制备式（1）化合物的方法：其中R1是烷基，芳基烷基，烯丙基，烷氧羰基，芳基烷氧羰基，酰基或炔基；R2是取代苯基，特别是3,4-亚甲二氧基苯基；X是氢或易于去除的基团，例如氯，溴或碘。